Neue Ansätze zur zielgerichteten Behandlung solider Tumoren.Antisense Oligonukleotide und Immunotoxine zur tumorzellspezifischen ApoptoseinduktionMaximilian Posch234181.191.21.2.1101.2.2111.2.31.2.4121.3131.3.114151.3.21.3.3161.41.4.1171.4.1.11.4.1.2181.4.1.31.4.2191.4.2.11.4.2.21.4.2.3202212.12.2222.32.3.1232.3.22.3.33243.13.1.13.1.23.1.33.1.4253.1.53.1.63.1.73.1.8263.1.8.13.1.8.23.1.9273.1.103.1.113.2283.2.13.2.23.2.34294.14.1.14.1.1.1304.1.1.24.1.1.3314.1.2324.1.2.1334.1.2.24.1.3344.1.3.1354.1.3.2364.1.3.337384.2394.2.14.2.1.1404.2.1.2414.2.24.2.2.1424.2.2.2435445.15.1.15.1.2455.1.3465.1.4475.25.2.1485.2.249506516.1525354556.25657 Abkürzungen:7 Referenzen5859606162 63 Lebenslauf von Maximilian Posch64 Veröffentlichungen:65deInhaltsverzeichnisHilfe Referenzen 1. Adams JM, Cory S. The Bcl-2 Protein family: arbiters of cell survival. Science 281, 1322 (1998). 2. Reed JC. Double identity for proteins of the Bcl-2 family. Nature 387, 773-776 (1997). 3. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81, 151-157 (1993). 4. Dole MG, Jasty R., Cooper MJ, Thompson CB, Nunez G, Castle VP. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Research 55, 2576-2582 (1995). 5. Simoes-Wüst AP, Olie R., Gautschi O, Leech SH, Häner R, Hall J, Fabbro D, Stahel RA, Zangemeister-Wittke U. bcl-xL antisense treament induces apoptosis in breast carcinoma cells. International Journal of Cancer 87, 582-590 (2000). 6. Zangemeister-Wittke U, Schenker. T, Luedke GH, Stahel RA. Synergistic cytotoxity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. British Journal of Cancer 78, 1035-1042 (1998). 7. Nita ME, Ono-Nita S, Tsuno N, Tominaga O, Takenoue T, Sunami E, Kitayama J, Nakamura Y, Nagawa H. Bcl-xL Antisense sensitize human colon cancer cell line to 5-Fluorouracil. Japanese Journal of Cancer 91, 825-832 (2000). 8. Webb A, Cunningham D., Cotter C, Clarke PA, di Stefano F, Ross P, Corbo M, Dzienwanowska Z . Bcl-2 antisense therapy in patients with non-Hodkin lymphoma. The Lancet 349, 1137-1141 (1997). 9. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, Hoermann M, Hollenstein U, Wolff K, Pehamberger H. Chemosensitisation of malignant melanoma by bcl-2 antisense therapy. The Lancet 356, 1728-1732 (2000). 10. Zangemeister-Wittke U, Leech S., Olie RA, Simoes-Wüst AP, Gautschi O, Luedke GH, Natt F, Häner R, Martin P, Hall J, Nalin C. M, Stahel RA, A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clinical Cancer Research 6, 2547-2555 (2000). 11. Balzar M, Winter. M., de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-Cam). Journal of Molecular Medicine 77, 699-712 (1999). 12. Piythilake JP, Frost A., Weiss H, Manne U, Heimburger DC, Grizzle WE. The expression of Ep-Cam in squamous cell cancers of the lung. Human Pathology 31, 482-487 (2000). 13. Kosternik JG, Jonge MW, Smit EF, Piers DA, Kengen RA, Postmus PE, Shochat D, Groen HJ . Pharmakokinetics and scintigraphy of indium-111-DTPA-MOC-31 in small cell lung cancer. Journal of Nuclear Medicine 36, (1995). 14. Elias DJ, Kline LE., Robins BA, Johnson HC, Pekny K, Benz M, Robb JA, Walker LE, Kosty M, Dillmann RO. Monoclonal antibody KS1/4-methotrexate immuno conjugates studies in non-small cell carcinoma. American Journal of Respiratory Crit. Care Medicine 150, (1994). 15. Zimmermann S, Wels W, Froesch BA, Gerstmayer B, Stahel RA, Zangemeister-Wittke U. A novel immunotoxin recognisng the epithelial glycoprotein-2 has potent antitumoral activity on chemotherapy-resistant lung cancer . Cancer Immunology Immunotherapy 44, 1-9 (1997). 16. Willuda J, Honegger A., Waibel R, Schubiger PA, Stahel RA, Zangemeister-Wittke U, Plückthun A. High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithehelial glykoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Research 59, 5758-5767 (1999). 17. Greenlee RT, Murray T., Bolden S, Wingo PA. Cancer Statistics 2000 . Cancer Journal for Clinicians 50, 7-33 (2000). 18. Miki Y. A strong candidate for the breast and ovarian cancer susceptebility gene BRCA1. Science 266 (1994). 19. Zhang GJ, Kimijima I., Tsuchiya A, Abe R. The role of Bcl-2 expression in breast carcinomas. Oncology Reports 5, 1211-1216 (1998). 20. Fernandez Y, Espana L., Manas S, Fabra A, Sierra A. Bcl-xL promotes metastasis of breast cancer by induction of cytokines resistance . Cell Death and Differentiation 7, 350-359 (2000). 21. Nicholson DW . From bench to clinic with apoptosis-based therapeutics. Nature 407, 810-816 (2000). 22. Goldstein P. Controlling cell death. Science 175, 1081-1882 (1997). 23. Chinnaiyan AM, O’Rourke. K., Lane BR, Dixit VM. Interaction of CED-4 with CED-3 and CED-9: A molecular framework of cell death. Science 275, 1122-1126 (1997). 24. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X . Apaf-1 a human protein homologous to C. elegans CED-4 participates in cytochrome c-dependent activation of caspase-3. Cell 90, 405-413 (1997). 25. Tsujimoto Y, Cossman J, Jaffe E, Croce C. Involvment of the bcl-2 gene in human follicular lymphoma. Science 228, 1440-1443 (1985). 26. Hockenberry D, Nunez. G., Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348, 334-336 (1990). 27. Hu Y, Bcl-xL interacts with Apaf-1 and inhibits Apaf-1 dependent caspase 9 activation. PNAS 95, 4386-4391 (1998). 28. Tsujimoto Y, Shimizu S. Bcl-2 family: Life-or-death switch. FEBS Letters 466 (2000). 29. Knudson CM, Korsmeyer SJ. Bcl-2 and Bax function independently to regulate cell death. Nature Genetics 16, 358-363 (1997). 30. Tudor G, Aguilera A., Halverson DO, Laing ND, Sausville EA,. Susceptebility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein. Cell Death and Differentiation 7, 574-586 (2000). 31. Nita ME, Nagawa H, Tominaga O, Tsuno N, Fujii S, Sasaki S, Fu CG, Takenoue T, Tsuruo T, Muto T. 5-Fluorouracil induces apoptosis in human colon colon cancer cell lines with modulation of Bcl-2 family proteins. British Journal of Cancer 78, 986-992 (1998). 32. Kawakami K, Tsukuda M., Mizuno H, Nishimura G, Ishii A, Hamajima K. Alteration of the Bcl-2/Bax status of head and neck cancer cell lines by chemotherapeutic agents. Anticancer Research 19, 3927-3932 (1999). 33. Gulbins E, Jekle K. Ferlinz K., Grassme H, Lang F. Physiology of apoptosis. American Journal of Renal Physiology 279, 605-615 (2000). 34. Antonsson B, Inhibition of Bax chanell-forming activity by Bcl-2. Science 277, 370-372 (1997). 35. Shimizu S, Nita M, Tsujimoto Y . Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399, 483-487 (1999). 36. Schendel SL. Channel formation by antiapoptotic protein Bcl-2. PNAS 94, 5113-5118 (1997). 37. Minn AJ. Bcl-xL forms an ion channel in synthetic lipid membranes. Nature 385, 353-357 (1997). 38. Schlesinger PB. Comparisons of the ion channel characteristics of proapoptotic Bax and antiapoptotic Bcl-2. PNAS 94 (1997). 39. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X Prevention of apoptosis by Bcl-2: Release of cytochrom c from mitochondria is blocked. Science 275, 1129-1135 (1997). 40. Haldar S, Croce CM. Taxol induces Bcl-2 phorphorylation and death of prostate cancer cells. Cancer Research 56, 1253-1255 (1996). 41. Blagosklonny M, Fojo T. Molecular effects of paclitaxel: myths and reality. International Journal of Cancer 83, 151-156 (1999). 42. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 281, 1305 (1998). 43. Thornberry NA, Lazebnik Y. Caspases: Enemies within. Science 281, 1312 (1998). 44. Cheng EH, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K, Hardwick JM Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 278, 1966-1968 (1997). 45. Yuen AR, Sikic BI. Clinical studies of antisense therapy in cancer. Frontiers in Bioscience, 588-593 (2000). 46. Kuss B, Cotter F . Antisense-time to shoot the messenger. Annals of oncology 10, 495-503 (1999). 47. Reed JC . Promise and problems of Bcl-2 antisense therapy . Journal of the National Cancer Institute 89, 988-990 (1997). 48. Bennett CF, Chiang MY., Chan H, Ellen J, Shoemaker E, Mirabelli CK . Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Molecular Pharmacology 41, 1023-1033 (1992). 49. Sausville EA, Haedlee D, Stetler M, Jaffe ES, Solomon D, Figg WD, Kopp WC, Rager H, Steinberg SM, Gethie V, Schindler J, Uhr J, Wittes RE, Vitetta ES . Continuous infusion with the anti CD-22 Immunotoxin IgG-RFB4-SMPT-dgA in patients with b-cell lymphoma: A phase 1 study. Blood 85, 3457-3465 (1995). 50. Laske DW, Youle RJ., Oldfield YE. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumor. Nature Medicine 3 (12) 1362-1368 (1997). 51. Fitzgerald D, Pastan I. Pseudomonas exotoxin and recombinant immunotoxins derived from it. Annals New York Academy of Sciences, 740-745. 52. Keppler-Hafkemeyer A, Brinkmann U, Pastan I. Role of caspases in Immunotoxin-induced apoptosis of cancer cells. Biochemistry 37, 16934-16942 (1998). 53. Mesmaeker A, Häner R., Martin P, Moser HE . Antisense Oligonucleotides. Accounts of Chemical Research 28, 366-374 (1995). 54. Miyake H, Chi K, Gleave ME. Antisense TRPM-2 Oligodeoxynucleotides chemosensitize human androgen-independent PC-3 cancer cells both in vivo and in vivo. Clinical Cancer Resarch 6, 1655-1663 (2000). 55. Qiang-Yuan L, Stein CA. Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alterattion in bcl-xL and bak expression. Clinical Cancer Research, 2039-2046 (1997). 56. Poruchyuske MS, Wang EE, Rudin CM, Blgosklonny MV, Fojo T. Bcl-xL is phosphorylated following microtubule disruption Cancer Research 58, 3331-3338 (1998) 57. Chou T-C, Talalay P. Quantitative Analysis af dose-effect relationships: The combined effect of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation 22, 27-55 (1983). 58. Blagoskonny MV, Neckers. LM. Oligonucleotides protect cells from the cytotoxity of several anti-cancer drugs. Anti-Cancer Drugs 5, 437-442 (1994). 59. Gautschi O, Tschopp S., Leech SH, Olie RA, Simoes-Wüst AP, Baumann B, Hall J, Odermatt B, Stahel RA, Zangemeister-Wittke U. Potent anti-tumor activity of a Bcl-2/Bcl-xL bispecific antisense oligonucleotide against tumor cell lines of diverse histological origin. Journal of the National Cancer Institute 93, 463-471 (2000). 60. Tortora G, Bianco R, Damiano V, Fontanini G, De Placido S, Bianco AE, Ciardiello F. Oral Antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis and growth factor production. Clinical Cancer Research 6, 2506-2512 (2000). 61. Yamori T, Sato S, Chikazawa H, Kadota T. Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. Japanese Journal of cancer research 88, 1205-1210 (1997). 62. Kubota T, Matsuzake S., Hoshiya Y, Watanabe M, Kitajima M, Asanuma F, Yamada Y, Koh JI . Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice. Journal of surgical oncology 64, 115-121 (1997). 63. Gurnani M, Lipari P., Dell J, Shi B, Nielsen L . Adenovirus mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate and breast cancer. Cancer chemotherapeutic pharmacology 44, 143-151 (1999). 64. Ogasawara Y, Doihara H., Shiroma K, Kanaya Y, Shimizu N . Effects of experimental chemoendocrine therapy with a combination of a pure antiestrogen an 5-Fluorouracil on human breast cancer cells implanted in nude mice. Japanese Journal of Surgery 29, 149-156 (1999). 65. Keppler-Hafkemeyer A, Brinkmann U., Pastan I. Role of caspases in Immunotoxin apoptosis in cancer. Biochemistry 37, 16934-16942 (1998). 66. Simonian PL, Grillot DM, Nunez G. Bcl-2 and bcl-xL can differentially block chemotherapy-induced cell death. Blood 90, 1208-1216 (1997). 67. Teixeira C, R. J., Pratt MA. Estrogen promotes chemotheraeutic drug resistance by a mechanism involoving bcl-2 protooncogene expression in hman breast cancer cells. Cancer Research 55, 3902-3907 (1995). 68. Maurer CA, Friess H., Bühler S, Wahl B, Graber H, Zimmermann A, Büchler M. Apoptosis inhibiting factor Bcl-xL might be the crucial member of the Bcl-2 family gene family in colorectal cancer. Digestive Diseases and Sciences 43, 2641-2648 (1998). 69. Nieves-Neira W, Pytilake Y. Apoptotic response to camtothecin and 7-Hydroxystaurosporine (Ucn-01) in the human breast cancer cell lines of the NCI anticancer drug screen: Multifactorial relationsship with topoisomerase 1, Protein Kinase C, Bcl-2, p53, MDM-2 and caspase pathways. International Journal of Cancer 82, 396-404 (1999) 70. Olopade OI, Adeyanju MO, Safa AR, Hagos F, Mick R, Thompson CB, Recant WM. Overexpression of Bcl-x protein in primary breast cancer is associated with high tumor grade and nodal metastasis. Cancer Journal Sci. Am. 3, 230-237 (1997). 71. Pratt M . Estrogen withdrawal-induced human breast cancer tumor regression in nude mice is prevented by Bcl-2. FEBS Letters 440, 403-408 (1998). 72. Olie RA, Simoes-Wüst AP, Baumann B, Leech SH, Fabbro D, Stahel RA, Zangemeister-Wittke U. A novel antisense oligonucletide targeting survivin expression induces apoptosis and sentizes lung cancer cells to chemotherapy. Cancer Research 60, 2805-2809 (2000). 73. Han Z, Chatterjee D., Early J, Pantazis P, Hendrickson EA, Wyche JH. Isolation and characerization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from Bcl-2 to Bcl-xL. Cancer Research 56, 1621-1628 (1996). 74. Pai LH, Wittes. R., Setser A, Willingham C, Pastan I. Treatment of advanced solid tumors with immunotoxin LMB-1: An antibody linked to pseudomonas extotoxin. Nature Medicine 2, 350-353 (1996). 75. Kreitman RJ, Pastan I. Accumulation of recombinant immunotoxin in a tumor in vivo: Fewer than 1000 molecules per cell are sufficient to complete tumor responses. Cancer Research 58, 968-975 (1998). 76. Fridman JS, Benedict MA, Maybaum J . bcl-xS-induced cell death in 3T3 cells does not require or induce caspase activation. Cancer Research 59, 5999-6004 (1999) 77. Hartmann G, Bidlingmaier M, Eigler A, Hacker U, Endres S. Antisense-Oligonukleotide: Nukleinsäuren zur gezielten Synthesehemmung krankheitsfördernder Proteine Deutsches Ärzteblatt 95, 1524-1530 (1998) 78. URL: www.clinicalTrials.gov Februar 2001 A service of the National Institute of Health (USA) 78. Haldar S, Chintapalli J, Croce CM. Taxol induces Bcl-2 phosphorylation and death of prostate cancer cells Cancer Research 53, 4978-4989 (1996) 79. Miayake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer cells with the use of antisense bcl-2 oligodeoxynucleotides Journal of the National cancer Institute 5, 34-41 (2000) 80. Wang H, Cai Q, Zeng X, Yu D, Agrawal S, Zhang R Antitumor activity of a mixed-backbone antisense oligonucleotide targeted to the RI α subunit of protein kinase A after oral administration PNAS 96, 13989-13994 (1999)